MIRAGE Study: A Possible New Path for More Aggressive Meningiomas
Among tumors that develop inside the skull, meningioma is one of the most common. Unlike other brain tumors, it does not arise from brain tissue itself but from the meninges, the membranes that surround and protect the brain and spinal cord. In most cases, meningiomas grow slowly and behave in a benign way, but this is not always the case.
About one in five meningiomas consists of more aggressive forms, classified as grade 2 (atypical) or grade 3 (anaplastic). These tumors have a higher tendency to recur over time and can become particularly challenging to manage. They occur more frequently in older adults, especially after the age of 65, and are more common in women.
Today, treatment for meningioma mainly relies on surgery and radiotherapy. When the tumor can be completely removed through surgery, outcomes are often favorable. In cases where complete removal is not possible, or when the tumor is more aggressive, radiotherapy is used to reduce the risk of recurrence. However, when a grade 2 or 3 meningioma returns after these treatments, the situation becomes much more complex. Therapeutic options become limited, and at present, there are no medications considered a truly effective standard of care for these recurrent forms.
It is precisely in this context that the MIRAGE clinical study was developed, with the goal of offering a possible new opportunity to patients facing this difficult stage of the disease. Researchers are evaluating the effectiveness of a drug called Regorafenib, a targeted therapy already used in other cancers. This oral medication works by blocking key mechanisms that tumors rely on to survive, particularly the formation of new blood vessels that supply nutrients and the signals that promote tumor growth and spread.
The aim of the study is to determine whether this drug can keep the disease stable for a longer time compared with treatments currently used in these cases, such as hydroxyurea or bevacizumab. In other words, researchers want to see whether Regorafenib can delay tumor progression in people who have already undergone surgery and radiotherapy and who are no longer candidates for further local treatments.
MIRAGE therefore represents a concrete effort to turn promising laboratory research into a new therapeutic option for patients who currently have few alternatives. In situations like this, clinical trials are not just experiments—they can become a real opportunity to access innovative treatments.
If you or a loved one are facing a recurrent aggressive meningioma, it may be helpful to learn more about the possibility of participating in this study and to discuss it with your neuro-oncology team. Being aware of research opportunities is an important step toward not feeling alone when dealing with a complex disease.
